qDSA Blood Flow Measurement for Liver Cancer

Overseen By Radiology Coordinators

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: University of Wisconsin, Madison

Disqualifiers: Pregnancy, Kidney disease, Contrast allergy, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 1

Duration: 1 hour

20 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a new technique called quantitative digital subtraction angiography (qDSA) to measure blood flow during liver tumor treatment. The goal is to help doctors block the right amount of blood flow to the tumor during liver embolization, a procedure that cuts off the tumor's blood supply. This could improve treatment effectiveness. Individuals undergoing liver tumor treatment with embolization, who do not have severe kidney problems or allergies to the contrast dye used in the procedure, might be suitable for this trial. As an unphased trial, this study offers the opportunity to contribute to innovative research that could enhance future liver tumor treatments.

Do I need to stop my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.

What prior data suggests that this technique is safe for measuring blood flow during liver embolization procedures?

Research has shown that the qDSA technique is generally easy for patients to handle. This method checks blood flow by using natural changes in image contrast caused by blood movement. Studies have found that qDSA can be performed with lower radiation levels, enhancing patient safety. Researchers monitor participants for up to six months after the procedure for safety. So far, studies have reported no major side effects, suggesting that qDSA is a safe way to measure blood flow during liver procedures. ^{1 2 3 4 5}

Why are researchers excited about this trial?

Unlike standard treatments for liver cancer, which often involve surgery, chemotherapy, or radiofrequency ablation, the qDSA Blood Flow Measurement technique is unique because it offers a non-invasive way to assess blood flow changes in the liver. This method provides real-time, precise insights into the effectiveness of transarterial embolization (TAE), a procedure used to block blood flow to cancerous tumors. Researchers are excited about this technique because it could enhance the precision of existing treatments, leading to better outcomes and potentially fewer side effects for patients.

What evidence suggests that the qDSA technique is effective for measuring blood flow during liver embolization?

Research has shown that the qDSA technique can effectively track changes in blood flow during liver tumor treatments. In this trial, participants undergoing TAE of the liver will have their blood flow measured using the qDSA technique. Studies have demonstrated that qDSA accurately measures blood flow speed, highlighting clear differences when blood flow decreases. This precision helps doctors ensure the right amount of blood flow reduction to the tumor, which is crucial for effective treatment. Additionally, qDSA enhances the detection of liver cancers, especially in complex cases like those with cirrhosis, a liver disease. Overall, qDSA supports existing liver cancer treatments by ensuring precise blood flow management. ^{1 2 3 6 7}

Who Is on the Research Team?

Paul Laeseke, MD, PhD

Principal Investigator

UW School of Medicine and Public Health

Are You a Good Fit for This Trial?

This trial is for up to 20 people who are undergoing liver transarterial embolization, a treatment for liver tumors. Participants will have one study visit with follow-ups for data collection over six months.

Inclusion Criteria

Give voluntary, written informed consent to participate in this study and willing to comply with study-related evaluation and procedure schedule

Exclusion Criteria

Pregnancy or breastfeeding

Patients with a physical or psychological condition that would impair study participation

The patient is judged unsuitable for study participation by the Investigator for any other reason

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants undergo transarterial embolization (TAE) of the liver with qDSA blood flow measurement

1 hour

1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after the procedure, with data collection and analysis

up to 6 months

What Are the Treatments Tested in This Trial?

Interventions

• qDSA Blood Flow Measurement

Trial Overview The trial is testing qDSA, a new technique to measure blood flow during liver embolization procedures. It aims to help doctors verify the reduction in tumor blood supply by assessing flow before, during, and after treatment.

How Is the Trial Designed?

Group I: Participants Undergoing TAE of the Liver Experimental Treatment 1 Intervention

Who Is Running the Clinical Trial?

University of Wisconsin, Madison

Lead Sponsor

Trials

1,249

Recruited

3,255,000+

Siemens Medical Solutions

Industry Sponsor

Trials

26

Recruited

6,100+

Citations

1. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC7855448/

A Quantitative Digital Subtraction Angiography Technique for ... Results. Blood flow velocities calculated using qDSA showed a statistically significant difference (p<0.01) between partial- and sub-stasis ...

2. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC6283217/

Assessment of small hepatocellular carcinoma: perfusion ... Abstract. To explore the role of quantitative digital subtraction angiography (QDSA) in the diagnosis of small hepatocellular carcinoma (HCC).

3. withpower.com withpower.com/trial/phase-transarterial-embolism-2-2025-59438

qDSA Blood Flow Measurement for Liver Cancer The qDSA technique could help doctors ensure the blood flow to the tumor is decreased by the right amount by calculating blood flow before, during, and after ...

4. researchgate.net researchgate.net/figure/Cross-tabulation-of-the-time-concentration-curves-and-the-selective-regions-of-interest_tbl1_329296261

Cross-tabulation of the time-concentration curves and ... Results: Blood flow velocities calculated using qDSA showed a statistically significant difference (p<0.01) between partial- and sub-stasis endpoints, whereas ...

5. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC11150548/

Advances in gross tumor target volume determination ... QDSA, Accurately measure arterial blood flow and improve the detection rate of HCC in the background of cirrhosis (33). SWI, The positive rate ...

6. researchgate.net researchgate.net/publication/382200775_Quantitative_Digital_Subtraction_Angiography_Measurement_of_Arterial_Velocity_at_Low_Radiation_Dose_Rates

Quantitative Digital Subtraction Angiography Measurement ... This study demonstrates the feasibility of quantitative blood velocity measurements from angiographic images acquired at reduced radiation dose ...

7. mdpi.com mdpi.com/2072-6694/16/23/3933

Hepatocellular Carcinoma Surveillance Strategies: Major ... CEUS improves the capability of conventional US by using microbubble contrast agents to enhance the visualization of blood flow and tumor vascularity [14]. CEUS ...